Ziprasidone Treatment Guidelines

FDA-Approved Indications

• The American Academy of Child and Adolescent Psychiatry recommends ziprasidone for acute treatment of manic or mixed episodes in adults with bipolar I disorder, with a typical dosing range of 40-80 mg twice daily with food 2, 3
• The American Academy of Child and Adolescent Psychiatry also recommends ziprasidone as adjunctive therapy to lithium or valproate for maintenance treatment of bipolar I disorder 2, 3

Important Off-Label Uses

• Ziprasidone 20 mg IM is highly effective for rapid reduction of acute agitation with onset within 15 minutes, regardless of underlying cause, with a maximum daily IM dose of 40 mg/day 1, 4
• The American Academy of Child and Adolescent Psychiatry suggests that ziprasidone can be used off-label as an antiemetic for nausea and vomiting in gastroparesis due to its dopamine-receptor blocking effects 4, 5

Critical Prescribing Considerations

• The American Heart Association recommends avoiding ziprasidone in patients with recent acute myocardial infarction, baseline QT prolongation, or those taking other QT-prolonging medications, as it prolongs the QTc interval 4
• The American Diabetes Association notes that ziprasidone is one of the most weight-neutral antipsychotics with minimal impact on cholesterol, triglycerides, or glycemic control, making it suitable for patients with metabolic concerns 1, 4

Common Pitfalls to Avoid

• The American Academy of Child and Adolescent Psychiatry advises against using ziprasidone for hiccups, as there is no evidence supporting this indication and safer alternatives exist 5
• The American Heart Association recommends cardiac screening before initiation of ziprasidone, particularly ECG assessment for QTc prolongation, to avoid potential cardiac safety concerns 4